INTERCEPT is not approved for sale in the United States and certain other countries.

SIGN UP FOR OUR
E-NEWSLETTER

INTERCEPT eNews delivers product news & information updates.

2006

2006 INTERCEPT Conference Abstracts

 

Jump to Conference
ASBMT NATA DGTI
ICEID SETS AABB
EBMT ISBT ASH

 

American Society for Blood and Marrow Transfusion (ASBMT)
February 16-20, 2006 | Honolulu, HI, USA 

  • Grabmer C, Lass-Floerl C, Allersdorfer D et al. Bacterial Contamination of Platelet Concentrates: Inactivate or screen?
    [Poster PDF]

International Conference on Emerging Infectious Diseases (ICEID)
March 19-22, 2006 | Atlanta, Georgia   

  • Sawyer L, Benach J, Bernard K et al.   Inactivation of Emergent Blood-borne Pathogens in Plasma and Platelets Using the INTERCEPT Blood System.
    [Poster PDF]

European Group for Blood and Marrow Transplantation (EBMT)
March 23-24, 2006 | Hamburg, Germany   

  • Schlenke P, Lin L, Corash L et al. Protection Against TA-GvHD in Blood Transfusion: Is Gamma-irradiation the Only Answer?
    [Poster PDF]

Network for Advancement of Transfusion Alternatives (NATA)
April 6-7, 2006 | Malaga, Spain

  • Lozano M, Galan A, Mazzara R et al. Hemostatic function of Leucocyte-Reduced Buffy Coat Derived Platelet Concentrates (BCPC) Treated With INTERCEPT® Are Well Conserved After 7 Days of Storage: Studies In A Whole Blood Flow System.

Sociedad Espanola de Transfusion Sanguinea (SETS)
June 8-10, 2006 | Palma de Mallorca, Spain    

  • Castro E, Girones N, Bueno JL et al.  The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for the Inactivation of Trypanosoma cruzi (T. cruzi) in Buffy Coat Derived Platelet Components.
     
  • Ontañón A, Romón I, Amunarriz C et al.  Evaluation Of INTERCEPT Blood System® (Baxter-Cerus) For Pathogen Inactivation: The Effect Of Implementation On The Quality Of The Platelets And On The Logisitcs Of The Centre.
    [Poster PDF]

International Society for Blood Transfusion (ISBT)
September 2-7, 2006 | Cape Town, South Africa

  • Rasonglès P, Isola H, Kientz D et al. Rapid Implementation of Photochemical Pathogen Inactivation (INTERCEPT) for Preparation of Platelet Components During an Epidemic of Chikungunya Virus.
     
  • Ontanon A, Romon I, Hurtado C et al.  Inactivation of High Levels of Bacteria Using the INTERCEPT Blood System Under Routine Blood Bank Procedures.
    [Poster PDF]
     
  • Osselaer JC, Messe N, Hervig T et al.  A Prospective Observational Cohort Safety Study of 5,106 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT).
    [Poster PDF]
     
  • Osselaer JC, Doyen C, Chatelain C et al. Impact of Photochemical Treatment (INTERCEPT) on Platelet Use In Routine Practice.
    [Poster PDF]
     
  • Osselaer JC, Debry C, Goffaux M et al. Photochemical Pathogen Inactivation of High-dose Apheresis Platelet Concentrates Using the INTERCEPT Blood System.
    [Poster PDF]
     
  • Schlenke P, Franck V, Lin L et al. Storage of Apheresis and Pooled Buffy-coat Platelet Concentrates Treated with Pathogen Inactivation Using the INTERCEPT Blood System.
    [Poster PDF]
     
  • Van Haute I, Van Lancker S, Bordon V et al. Therapeutic Effi cacy and Safety of Transfusion of Pathogen-Inactivated Platelets to Pediatric Patients.
    [Poster PDF]
     
  • Witt V, Fischmeister G, Stiegler G et al. Transfusion of Pathogen Inactivated Platelet Concentrates in Children.
     
  • Vignoli C, Dombey AM, Cantaloube JF et al. Photochemical Treatment with Amotosalen and UVA Light Inactivated High Titers of an Emerging South France Viral Strain of West Nile Virus.
    [Poster PDF]
     
  • Stiegler G, Witt V, Mörtl P et al. Routine Production of INTERCEPT-Treated Apheresis Platelet Concentrates for Pediatric Patients.
     
  • Castro E, Gironés N, Bueno JL et al. The Efficacy of Photochemical Treatment with Amotosalen and UVA (INTERCEPT) for the Inactivation of Trypanosoma cruzi (T.cruzi) in Buffy Coat Derived Platelet Components.
    [Poster PDF]
     
  • De Meuter R, Bastin G, Lambermont M. Evaluation of the INTERCEPT Blood System for Amicus Apheresis Platelet Concentrates: Meeting Target Product Characteristics.
     
  • Sawyer L, Dupuis K, Sampson-Johannes A et al. Inactivation of Chikungunya Virus in Plasma and Platelets Using Helinx Technology, as Utilized in the INTERCEPT Blood System.
    [Poster PDF]
     
  • Cazenave JP, Isola H, Wiesel ML et al. Stability of Coagulation Factors in Plasma Prepared with Photochemical Treatment (INTERCEPT) Stored for One Year.
    [Poster PDF]
     
  • Osselaer JC, Debry C, Goffaux M et al. Coagulation Function in Fresh Frozen Plasma Prepared with Two Photochemical Treatment Methods
    [Poster PDF]
     
  • Corash L, Bass N, Petz L et al. Fresh Frozen Plasma for Management of Hemostasis During Minor and Major Surgical Procedures Associated With Coagulopathy.
    [Poster PDF]
     
  • Pinkoski L, Peterson T, Bayat J et al. Coagulation Factor Activity in 180 mL and 325 mL Units of Photochemically Treated Plasma (INTERCEPT Plasma) After Storage for 12 Months at -18ºC.
    [Poster PDF]
     
  • Misso S, Nigro M, Fratellanza G et al.  Platelet Concentrates Produced by the OrbiSac BC System and Treated with the INTERCEPT Blood System:  Evaluation of the in vitro Platelet Quality.
     
  • Erickson A, Schott MA, Lee VA et al.  A Modified Treatment Process for Preparation of S-303 RBC for Pathogen Inactivation in Three Different Additive Solutions Maintains RBC Function.
     
  • Mababangloob R, Patel N, Kinsey J et al.  Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.
     
  • North A, Garratty G, Schott MA et al.  A Modified Treatment Process for Preparation of S-303 RBC for Pathogen Inactivation Substantially Reduces the Potential for Cross-Reactivity.

Deutsche Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI)
September 19-22, 2006 | Frankfurt, Germany

  • Janetzko K, Bugert P, Lin L et al. Monitoring of the Photochemical Pathogen Inactivation Procedure for Platelet Concentrates by PCR and Bioanalyzer.
     
  • Schlenke P, Franck V, Lin L et al. In VITRO and in VIVO Evaluation of Platelet Concentrates Treated with Pathogen Inactivation Using the INTERCEPT Blood System.

American Association of Blood Banks (AABB)
October 21-24, 2006 | Miami Beach, Florida, USA

  • Corash L, Rasonglès P, Isola H et al. Photochemical Pathogen Inactivation for Preparation of Platelet Components During an Epidemic of Chikungunya Virus.
    [Poster PDF]
     
  • Erickson AC, Schott M, Lee VA et al.  A Modified Process for Preparation of S-303 RBC for Pathogen Inactivation in Three Different Additive Solutions Maintains RBC Function.
     
  • Mababangloob R, Patel N, Kinsey J et al.  Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.
     
  • North A, Garratty G, Schott M et al.  A Modified Process for Preparation of S-303 for Pathogen Inactivation Substantially Reduces Potential for Reactivity.
     
  • Pinkoski L, Peterson T, Singh Y et al. Coagulation Factor Activity in Photochemically Treated Plasma Prepared From Previously Frozen Plasma.
    [Poster PDF]
     
  • Pinkoski L, Peterson T, Singh Y et al.  Coagulation Factor Activity in Photochemically Treated Plasma After Storage at 18ºC or –25ºC.
    [Poster PDF]
     
  • Sawyer L, Hsu J, Bernard K et al. Inactivation of Emergent Blood-borne Pathogens in Plasma and Platelets.
    [Poster PDF]

American Society of Hematology (ASH)
December 9-12, 2006 | Orlando, Florida, USA
 

  • Cazenave JP, Isola H, Wiesel ML et al. Coagulation Factors In Therapeutic Apheresis Plasma Held For 18 Hours At Ambient Temperature Prior To Pathogen Inactivation (INTERCEPT™).
    [Poster PDF]
     
  • Cazenave JP, Isola H, Wiesel ML et al. Coagulation Factor Activity In Therapeutic Plasma Prepared From Whole Blood With Pathogen Inactivation (INTERCEPT™) Treatment.
     
  • Corash L, Cognasse F, Osselaer JC et al. Cytokines In Platelet Components Associated With Acute Transfusion Reactions: The Role of sCD40L.
    [Poster PDF]
     
  • Corash L, Cognasse F, Osselaer JC et al. Release of Immune Modulation Factors From Platelet Concentrates During Storage After Photochemical Pathogen Inactivation.
    [Poster PDF]
     
  • Erickson AC, Schott MA, Lee VA et al.  A Modified S-303 Treatment Process for Pathogen Inactivation of RBC in Multiple Additive Solutions Maintains RBC Function and Reduces Immunologic Activity.
     
  • Mueller M, Pfeiffer HU, Rheinschmidt M et al. Effects of Pathogen Inactivation Using Amotosalen on Coagulation Parameters in Apheresis and Whole Blood Derived Fresh Frozen Plasma in a Large Blood Bank Setting.
     
  • Mababangloob R, Patel N, Kinsey J et al.  Inactivation of Pathogens in Red Blood Cells by a Modified Treatment Process Utilizing S-303 and Glutathione.
Untitled Document